Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of “Buy” from Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) has received a consensus rating of “Buy” from the nine research firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $13.33.

ROIV has been the topic of several recent analyst reports. Zacks Investment Research lowered Roivant Sciences from a “hold” rating to a “sell” rating in a research report on Friday, February 18th. Cantor Fitzgerald assumed coverage on Roivant Sciences in a research report on Friday, April 29th. They set an “overweight” rating and a $15.00 price target on the stock.

In related news, CAO Rakhi Kumar sold 7,281 shares of the stock in a transaction that occurred on Friday, March 25th. The stock was sold at an average price of $5.06, for a total transaction of $36,841.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Gline sold 8,509 shares of the stock in a transaction that occurred on Monday, April 25th. The shares were sold at an average price of $3.84, for a total value of $32,674.56. Following the sale, the chief executive officer now owns 1,404,448 shares of the company’s stock, valued at approximately $5,393,080.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 372,113 shares of company stock worth $1,902,993.

Large investors have recently made changes to their positions in the stock. Citigroup Inc. lifted its position in shares of Roivant Sciences by 1,803.6% in the 1st quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock worth $28,000 after acquiring an additional 5,447 shares during the period. Royal Bank of Canada lifted its position in shares of Roivant Sciences by 60,550.0% in the 1st quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock worth $30,000 after acquiring an additional 6,055 shares during the period. Hsbc Holdings PLC lifted its position in shares of Roivant Sciences by 25.4% in the 1st quarter. Hsbc Holdings PLC now owns 14,684 shares of the company’s stock worth $71,000 after acquiring an additional 2,978 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Roivant Sciences during the 1st quarter worth approximately $100,000. Finally, Susquehanna International Group LLP bought a new position in shares of Roivant Sciences during the 4th quarter worth approximately $108,000. Hedge funds and other institutional investors own 61.49% of the company’s stock.

Shares of NASDAQ ROIV opened at $3.65 on Friday. Roivant Sciences has a 12 month low of $2.52 and a 12 month high of $16.76. The business has a fifty day simple moving average of $4.21 and a 200-day simple moving average of $6.71.

Roivant Sciences (NASDAQ:ROIV – Get Rating) last posted its quarterly earnings results on Monday, February 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.18). The company had revenue of $24.34 million during the quarter, compared to analysts’ expectations of $10.13 million. On average, research analysts anticipate that Roivant Sciences will post -1.35 earnings per share for the current fiscal year.

Roivant Sciences Company Profile (Get Rating)

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.

Featured Articles